Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use
A Phase 4 Multicenter, Multinational, Prospective, Randomized, Placebo-Controlled, Double-Blinded Parallel Group Study to Assess Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D) in Patients Who Report Inadequate Control of IBS-D Symptoms With Prior Loperamide Use (RELIEF)
Sponsor: Allergan
This PHASE4 trial investigates Irritable Bowel Syndrome With Diarrhea and is currently completed. Allergan leads this study, which shows 12 recorded versions since 2016 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Mar 2019 — Jan 2021 [monthly]
Completed PHASE4
▶ Show 7 earlier versions
-
Jun 2018 — Mar 2019 [monthly]
Completed PHASE4
-
Mar 2018 — Jun 2018 [monthly]
Completed PHASE4
Status: Recruiting → Completed
-
Aug 2017 — Mar 2018 [monthly]
Recruiting PHASE4
-
Jun 2017 — Aug 2017 [monthly]
Recruiting PHASE4
-
Mar 2017 — Jun 2017 [monthly]
Recruiting PHASE4
-
Feb 2017 — Mar 2017 [monthly]
Recruiting PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE4
First recorded
Oct 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Allergan
For direct contact, visit the study record on ClinicalTrials.gov .